Your patient pool has not grown. Your coordinator hours have not multiplied. Your investigator's Wednesday afternoons have not expanded. But the number of studies competing for those finite resources just tripled.

This is not a hypothetical problem. It is Tuesday. And the question the site must answer -- honestly, rigorously, before any feasibility questionnaire is returned -- is not "Can we do all three?" It is: "What happens to each study, and to our existing commitments, if we try?"

I have watched this scenario unfold dozens of times, across therapeutic areas from oncology to metabolic disease to CNS. And the sites that handle it well share one characteristic: they treat their study portfolio the way an honest financial advisor treats an investment portfolio. They diversify. They know their capacity limits. And when a new opportunity arrives that would overextend the portfolio, they say so -- clearly, early, and with data.

The sites that handle it poorly share a different characteristic. They say yes to everything. Not out of dishonesty, but out of optimism -- a genuine belief that they will find the patients, find the time, make it work. And then enrollment lags across all three studies, protocol deviations accumulate, the coordinator burns out, and the site's reputation suffers in ways that take years to repair.

This lesson teaches you how to analyze competing study demands systematically, recognize when your therapeutic area portfolio has reached saturation, and make structured decisions about whether to accept, defer, or decline a new study opportunity.

Your patient pool has not grown. Your coordinator hours have not multiplied. Your investigator's Wednesday afternoons have not expanded. But the number of studies competing for those finite resources just tripled.

This is not a hypothetical problem. It is Tuesday. And the question the site must answer -- honestly, rigorously, before any feasibility questionnaire is returned -- is not "Can we do all three?" It is: "What happens to each study, and to our existing commitments, if we try?"

I have watched this scenario unfold dozens of times, across therapeutic areas from oncology to metabolic disease to CNS. And the sites that handle it well share one characteristic: they treat their study portfolio the way an honest financial advisor treats an investment portfolio. They diversify. They know their capacity limits. And when a new opportunity arrives that would overextend the portfolio, they say so -- clearly, early, and with data.

The sites that handle it poorly share a different characteristic. They say yes to everything. Not out of dishonesty, but out of optimism -- a genuine belief that they will find the patients, find the time, make it work. And then enrollment lags across all three studies, protocol deviations accumulate, the coordinator burns out, and the site's reputation suffers in ways that take years to repair.

This lesson teaches you how to analyze competing study demands systematically, recognize when your therapeutic area portfolio has reached saturation, and make structured decisions about whether to accept, defer, or decline a new study opportunity.